Disclosed is the use of bupropion hydrobromide in the production of a medicament for the prevention and/or reduction of convulsions and/or seizures associated with bupropion administration, wherein the bupropion administration is for the treatment or prevention of major depressive disorder, bipolar depression mood disorder, other mood disorder, anxiety disorders, generalised anxiety disorder, panic disorder, post-traumatic stress disorder, nicotine addiction, obesity, attention-deficit hyperactivity disorder, restless legs syndrome, sexual dysfunction or Parkinson's disease.
